Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

Specimen Handling 184Magnetic Resonance Spectroscopy 139Biopsy 102Immunoglobulin G 38Disulfides 38Cisplatin 37Nivolumab 36Platinum 35Paclitaxel 351,2-diaminocyclohexaneplatinum II citrate 35Radiation 34Cyclophosphamide 34Carboplatin 33Taxes 32Radiotherapy 28X-Rays 27pembrolizumab 26Doxorubicin 25Bevacizumab 24olaparib 22atezolizumab 21Gemcitabine 19Vincristine 18Prednisone 17Etoposide 17Leucovorin 16Cytarabine 16fludarabine 15durvalumab 15Phantoms, Imaging 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Thalidomide × 30 days × Clear all
NCT00602641 2026-05-29

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
306 enrolled 12 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡